In this study, an emulsion solvent evaporation method was used to produce Eudragit RL (ERL) nanoparticles (NPs) loaded with simvastatin (SIM) for the treatment of ulcerative colitis (UC). Accordingly, the effects of different formulation variables on the properties of NPs were evaluated using the Box-Behnken design. The optimized NPs were then coated by Eudragit FS30D (EFS30D). Drug release was studied in different physiological environments. Colitis was induced by 3% of acetic acid in rats, which received NPs of SIM (10 mg/kg/day), mesalazine (150 mg/kg/day), blank NPs and normal saline orally for 5 days. Macroscopic histopathological evaluation and biochemical analysis, including myeloperoxidase (MPO) activity and malondialdehyde (MDA) level in the colon tissues, were carried out in this study. The optimized SIM-ERL NPs showed the particle size of 182.48 ± 4.57 nm, the polydispersity index of 0.29 ± 0.12, the zeta potential of 26.45 ± 4.57 mV, drug loading % of 34.64 ± 0.48, the encapsulation efficiency % of 98.68 ± 0.69, and the release efficiency % of 35.78 ± 1.37. Coating the optimized NPs with EFS30D caused an increase in particle size and a decrease in the zeta potential of NPs. The optimized SIM-EFS30D/RL NPs improved the macroscopic and histopathological scores. Also, MPO activity and MDA level were reduced significantly by NPs, as compared to the control group. Therefore, this drug delivery system can be an alternative to the previous treatments of UC.
GuanQ. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. Immunol Res2019; 1: 1–16.
2.
MokhtarNNawawiKHVerasingamJ, et al.A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia. BMC Public Health2019; 19: 1–550.
3.
MagroFDohertyGPeyrin-BirouletL, et al.ECCO position paper: Harmonization of the approach to ulcerative colitis histopathology. Crohn’s Colitis2020; 14: 1503–1511.
4.
ZhangJZhaoYHouT, et al.Macrophage-based nanotherapeutic strategies in ulcerative colitis. Control Release2020; 320: 363–380.
5.
ZeeshanMAliHKhanH, et al.Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease. Int J Pharmaceutics2019; 558: 201–214.
6.
KatoSIshibashiAKaniK, et al.Optimized management of ulcerative proctitis: when and how to use mesalazine suppository. Digestion2018; 97: 59–63.
7.
LautenschlägerCSchmidtCFischerD, et al.Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev2014; 71: 58–76.
8.
SolimanNAKeshkWARizkFH, et al.The possible ameliorative effect of simvastatin versus sulfasalazine on acetic acid induced ulcerative colitis in adult rats. Chem Biol Interact2019; 298: 57–65.
9.
KhaliliH. Statins for Inflammatory Bowel Disease: Expanding the Scope of Prevention. Am J Gastroenterol2016; 111: 1424–1426.
10.
MaheshwariRABalaramanRSailorGU, et al.Protective effect of simvastatin and rosuvastatin on trinitrobenzene sulfonic acid-induced colitis in rats. Indian J Pharmacol2015; 47: 17–21.
11.
WangSXieXLeiT, et al.Statins attenuate activation of the NLRP3 inflammasome by oxidized LDL or TNFa in vascular endothelial cells through a PXR-dependent mechanism s. Mol Pharmacol2017; 92: 256–264.
12.
Abd ElbaryAIbrahimHKHazaaBS. Formulation and evaluation of colon targeted tablets containing simvastatin solid dispersion. Drugs Ther Stud2011; 1: 1–16.
13.
JatwaniSRanaACSinghG, et al.Solubility and dissolution enhancement of simvastatin using synergistic effect of hydrophilic carriers. Der Pharm Lett2012; 3: 942–956.
14.
NaeemMChoiMCaoJ, et al.Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Des Devel Ther2015; 9: 3789–3799.
15.
VermaSKumarVMishraDN, et al.Colon targeted drug delivery: Current and novel perspectives. Int J Pharm Sci Res2012; 3: 1274–1284.
16.
NaeemMBaeJOshiMA, et al.Colon-targeted delivery of cyclosporine a using dual-functional eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomedicine2018; 13: 1225–1240.
17.
TuranlıYAcartürkF. Preparation and characterization of colon-targeted pH/time-dependent nanoparticles using anionic and cationic polymethacrylate polymers. Eur J Pharm Sci2022; 1: 1–16.
18.
Dos SantosAMCarvalhoSGMeneguinAB, et al.Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives. Control Release2021; 334: 353–366.
19.
MoghimipourERezaeiMKouchakM, et al.Effects of coating layer and release medium on release profile from coated capsules with Eudragit FS 30D: an in vitro and in vivo study. Drug Dev Ind2018; 44: 861–867.
20.
HalesDVlaseLPoravSA, et al.A quality by design (QbD) study on enoxaparin sodium loaded polymeric microspheres for colon-specific delivery. Eur J Pharm2017; 100: 249–261.
21.
ChourasiaM.KJainS.K. Design and Development of Multiparticulate System for Targeted Drug Delivery to Colon. Drug Deliv J2008; 11: 201–207.
22.
KrishnamachariYMadanPLinS. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm2007; 338: 238–247.
23.
HasanYPegahDFaizaM, et al.Risperidone attenuates acetic acid-induced colitis in rats through inhibition of TLR4/NF-kB signaling pathway. Immunopharmacol Immunotoxicol2020; 42: 464–472.
24.
MinaiyanMAsghariGHTaheriD, et al.Anti-inflammatory effect of Moringa oleifera Lam. seeds on acetic acid-induced acute colitis in rats. Avicenna J Phytomed2014; 4: 127–136.
25.
Motavallian-naeiniAMinaiyanMRabbaniM, et al.Anti-inflammatory effect of ondansetron through 5-HT 3 receptors on TNBS-induced colitis in rat. EXCLI2021; 3: 30–44.
26.
MinaiyanMMazraatiP. Hepatoprotective effect of metadoxin on acetaminophen-induce liver toxicity in mice. Adv Biomed Res2018; 7: 1–67.
27.
MandalBAlexanderKSRigaAT. Sulfacetamide loaded eudragit RL100 nanosuspension with potential for ocular delivery. J Pharm Sci2010; 13: 510–523.
28.
SharmaNMadanPLinS. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: A co-surfactant study. Asian J Pharm Sci2016; 11: 404–416.
29.
BudhianASiegelSJWineyKI. Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int J Pharm2007; 336: 367–375.
30.
AmanatSTaymouriSVarshosazJ, et al.Carboxymethyl cellulose-based wafer enriched with resveratrol-loaded nanoparticles for enhanced wound healing. Drug Deliv Transl Res2020; 1: 1–14.
31.
ChoonaraYEPillayVNdesendoVMK, et al.Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers. Colloids Surf B Biointerfaces2011; 87: 243–254.
32.
Romero-PérezAGarcía-GarcíaEZavaleta-ManceraA, et al.Designing and evaluation of sodium selenite nanoparticles in vitro to improve selenium absorption in ruminants. Vet Res Commun2010; 34: 71–79.
33.
Yurtdaş-KırımlıoğluGGörgülüŞ. Surface modification of PLGA nanoparticles with chitosan or Eudragit® RS 100: Characterization, prolonged release, cytotoxicity, and enhanced antimicrobial activity. J Drug Deliv Sci Technol2021; 61: 102–145.
34.
NarayananKSubrahmanyamVMVenkata RaoJ. A fractional factorial design to study the effect of process variables on the preparation of hyaluronidase loaded PLGA nanoparticles. Enzyme Res2014; 1: 1–10.
35.
NakatukaYYoshidaHFukuiK, et al.The effect of particle size distribution on effective zeta-potential by use of the sedimentation method. Adv Powder Technol2015; 26: 650–656.
36.
LamprechtAYamamotoHTakeuchiH, et al.A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J Control Release2005; 104: 337–346.
37.
JoseSSowmyaSCinuTA, et al.Surface modified PLGA nanoparticles for brain targeting of Bacoside-A. Eur J Pharm Sci2014; 63: 29–35.
38.
RafieiPHaddadiA. A robust systematic design: optimization and preparation of polymeric nanoparticles of PLGA for docetaxel intravenous delivery. Mater Sci Eng C2019; 104: 1–37.
39.
VarshosazJTaymouriSHamishehkarH, et al.Development of dry powder inhaler containing tadalafil-loaded PLGA nanoparticles. Res Pharm Sci2017; 12: 222–232.
40.
HasanAA. Formulation and evaluation of dorzolamide hydrochloride-loaded nanoparticles as controlled release drug delivery system. Asian J Pharm2012; 6: 67–73.
41.
OtrojMTaymouriSVarshosazJ, et al.Preparation and characterization of dry powder containing sunitinib loaded PHBV nanoparticles for enhanced pulmonary delivery. J Drug Deliv Sci Technol2020; 56: 1–11.
42.
PaivaLAFGurgelLADe SousaET, et al.Protective effect of Copaifera langsdorffii oleo-resin against acetic acid-induced colitis in rats. J Ethnopharmacol2004; 93: 51–56.
43.
GrulkeSFranckTGanglM, et al.Myeloperoxidase assay in plasma and peritoneal fluid of horses with gastrointestinal disease. Can J Vet Res2008; 72: 37–42.
44.
AliahmatNSNoorMRMYusofWJW, et al.Antioxidant enzyme activity and malondialdehyde levels can be modulated by Piper betle, tocotrienol rich fraction and Chlorella vulgaris in aging C57BL/6 mice. Clinics2012; 67: 1447–1454.
45.
GrottoDSanta MariaLValentiniJ, et al.Importance of the lipid peroxidation biomarkers and methodological aspects for malondialdehyde quantification. Quim Nova2009; 32: 169–174.
